Mabwell

SHANGHAI, April 23, 2026 Mabwell has announced the initiation of a Phase III clinical trial for its proprietary Nectin-4-targeting...

SHANGHAI, CHINA, April 14, 2026 Mabwell (688062.SH) has announced that SST001 (18F-FD4), an innovative α-synuclein-targeted PET tracer developed by...